Crossmark

Characteristics and outcomes of patients with heart failure and reduced left ventricular ejection fraction in relation to sodium-glucose cotransporter-2 inhibitor treatment: real-world data from the multicentre H2-registry

Crossref DOI link: https://doi.org/10.1007/s00392-026-02853-2

Published Online: 2026-02-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Leiner, Johannes https://orcid.org/0000-0003-3678-0208
Hohenstein, Sven

König, Sebastian

Kwast, Stefan

Nitsche, Anne

Seyfarth, Melchior

Baberg, Henning

Lauten, Alexander

Neuser, Hans

Staudt, Alexander

Tebbenjohanns, Jürgen

Andrié, René

Niehaus, Michael

Ferrari, Markus W.

Müller, Marlena

Schulte, Nora

Bode, Kerstin

Kuhlen, Ralf

Bollmann, Andreas
Funding

Funding for this research was provided by:

AstraZeneca Germany

Universitätsklinikum Leipzig
License Information

Text and Data Mining valid from 2026-02-02

Version of Record valid from 2026-02-02
More Information

Article History

Received: 16 September 2025

Accepted: 13 January 2026

First Online: 2 February 2026

Declarations

:

: Ethical approval for this study was given by the ethics committee of the University of Leipzig (AZ 116/21-ek) and by local ethics committees at each participating site. The H 2 -registry is conducted according to the requirements of ‘good clinical practice’ as well as to the principles outlined in the Declaration of Helsinki 1975.

: Dr. Mueller is a former employee of AstraZeneca GmbH. Dr. Schulte is an employee of AstraZeneca GmbH.

Document is current

Any future updates will be listed below